Alterations on peripheral blood B-cell subpopulations in very early arthritis patients

Rheumatology (Oxford). 2010 Jun;49(6):1082-92. doi: 10.1093/rheumatology/keq029. Epub 2010 Mar 7.

Abstract

Objective: To characterize circulating B-cell subpopulations of arthritis patients with <6 weeks of disease duration.

Methods: Peripheral blood samples were collected from very early untreated polyarthritis patients, with <6 weeks of disease duration, for flow cytometric evaluation of B-cell subpopulations. Samples from patients who were later diagnosed as RA [very early RA (VERA)] were also collected 4-6 weeks after starting a low dose of prednisone (5-10 mg) and 4 months after reaching the minimum effective dose of MTX. A matched healthy group was used as a control.

Results: VERA patients have a lower percentage of total peripheral blood memory B cells (CD19(+)CD27(+)) and a significant decrease in the frequency of circulating pre-switch memory B cells (CD19(+)IgD(+)CD27(+)) as compared with controls. Therapy with corticosteroids or MTX was unable to restore the normal frequencies of these B-cell subpopulations. A significant decrease in peripheral pre-switch memory B cells is equally observed in other early arthritis patients. Furthermore, no significant differences are found in the frequencies of CD4(+) and CD8(+) T cells in all patient groups.

Conclusions: In very early polyarthritis patients, there is a reduction in circulating pre-switch memory B cells. The reasons that may account for this effect are still unknown. Short-term corticosteroids and MTX do not seem to have a direct effect on circulating B-cell subpopulations in VERA patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Aged
  • Arthritis / drug therapy
  • Arthritis / immunology*
  • B-Lymphocyte Subsets / immunology*
  • Blood Cells / immunology
  • Case-Control Studies
  • Female
  • Flow Cytometry
  • Humans
  • Lymphocyte Count
  • Male
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Time Factors
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Methotrexate